Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease

Am J Hematol. 2022 Jul;97(7):E273-E276. doi: 10.1002/ajh.26568. Epub 2022 Apr 22.

Authors

Craig W Freyer¹, Shannon Gier², Alison Carulli¹, Saar I Gill², Elizabeth O Hexner², Alison W Loren², Mary Ellen Martin², David L Porter²

Affiliations

¹ Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Blood and Marrow Transplant and Cellular Therapy Program, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

PMID: 35413140
DOI: 10.1002/ajh.26568

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Basiliximab
Etanercept / therapeutic use
Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Immunosuppressive Agents / therapeutic use
Salvage Therapy
Steroids

Substances

Immunosuppressive Agents
Steroids
Basiliximab
Etanercept